MedTrace Logo

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

NCT00368251 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2023-05-31

Study results available
· View outcomes & findings →

Summary

The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).

Conditions

  • Unverricht-Lundborg Disease

Interventions

OTHER

Placebo

* Pharmaceutical Form: Tablet * Concentration: 2.5 mg, 25 mg and 50 mg * Route of Administration: Oral use

DRUG

BRV 2.5 mg

* Pharmaceutical Form: Tablet * Concentration: 2.5 mg * Route of Administration: Oral use

DRUG

BRV 25 mg

* Pharmaceutical Form: Tablet * Concentration: 25 mg * Route of Administration: Oral use

DRUG

BRV 50 mg

* Pharmaceutical Form: Tablet * Concentration: 50 mg * Route of Administration: Oral use

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • UCB Clinical Trial Call Center · +1 877 822 9493 (UCB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States
  • Canada
  • Finland
  • France
  • Israel
  • Russia
  • Serbia
  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368251 on ClinicalTrials.gov